Stock Price Movements, Campaigns, New Clinical Studies, and Approvals- Research Report on Actavis, Ariad Pharmaceuticals,

    Stock Price Movements, Campaigns, New Clinical Studies, and Approvals-
   Research Report on Actavis, Ariad Pharmaceuticals, DaVita, Celldex, and
                                   WellCare

PR Newswire

NEW YORK, December 5, 2013

NEW YORK, December 5, 2013 /PRNewswire/ --

Editor Note: For more information about this release, please scroll to bottom.

Today, Analysts' Corner announced new research reports highlighting Actavis
plc (NYSE: ACT), Ariad Pharmaceuticals, Inc. (NASDAQ: ARIA), DaVita Healthcare
Partners Inc. (NYSE: DVA), Celldex Therapeutics, Inc. (NASDAQ: CLDX), and
WellCare Health Plans, Inc. (NYSE: WCG). Today's readers may access these
reports free of charge - including full price targets, industry analysis and
analyst ratings - via the links below.

Actavis plc Research Report

On December 2, 2013, Actavis plc's stock (Actavis) rose 0.19%, ending the day
at $163.38. Over the previous three trading sessions, shares of Actavis gained
0.52%, compared to the S&P 500 which declined 0.10% during the same period.
The Full Research Report on Actavis plc - including full detailed breakdown,
analyst ratings and price targets - is available to download free of charge
at:

http://www.analystscorner.com/r/full_research_report/4997_ACT

Ariad Pharmaceuticals, Inc. Research Report

On December 2, 2013, Ariad Pharmaceuticals, Inc.'s (Ariad Pharmaceuticals)
stock rose 1.86%, ending the day at $4.93. Over the previous three trading
sessions, shares of Ariad Pharmaceuticals gained 5.34%, compared to the Nasdaq
Composite which gained 0.68% during the same period. The Full Research Report
on Ariad Pharmaceuticals, Inc. - including full detailed breakdown, analyst
ratings and price targets - is available to download free of charge at:

http://www.analystscorner.com/r/full_research_report/161c_ARIA

DaVita Healthcare Partners Inc. Research Report

On November 27, 2013, DaVita Healthcare Partners Inc. (DaVita)'s wholly-owned
subsidiary, DaVita Clinical Research (DCR), announced the launch of its
"Inspired to Give" campaign, which shares experiences of people behind
clinical research. DCR reported that the campaign began on November 12, 2013,
and will continue up to February 2014. According to DCR, this campaign will
include 18 videos featuring both clinical trial participants and researchers
sharing their personal experiences related to clinical research. DCR added
that videos will be available on YouTube, while 15-second versions will be
viewable on Instagram. DCR Chief Scientific Officer Dr. Harry Alcorn, said,
"We find that the driving force for most who participate in clinical trials is
that they have someone close to them who has a disease or illness and they
want to help that person. And in additional to being altruistic, trial
participants ultimately play a key role in the future of health care by
helping to develop medicine for others." The Full Research Report on DaVita
Healthcare Partners Inc. - including full detailed breakdown, analyst ratings
and price targets - is available to download free of charge at:

http://www.analystscorner.com/r/full_research_report/5986_DVA

Celldex Therapeutics, Inc. Research Report

On December 2, 2013, Celldex Therapeutics, Inc. (Celldex) announced that the
Company has initiated a randomized study (METRIC) of Glembatumumab vedotin
(CDX-011) in patients with metastatic triple negative breast cancers that
over-express glycoprotein NMB (gpNMB). The Company informed that glembatumumab
vedotin is an antibody-drug conjugate that targets and binds to gpNMB, a
protein expressed in breast cancer which promotes the migration, invasion and
metastasis of the disease. Further, Celldex informed that it is also highly
expressed in triple negative breast cancers where it is associated with higher
risk of recurrence. Thomas Davis, M.D., Senior Vice President and Chief
Medical Officer of Celldex said, "Currently, patients with triple negative
breast cancer have very limited treatment options and no targeted
interventions. We believe gpNMB could be an important marker in breast cancer
and that Glembatumumab vedotin holds significant potential as a possible
targeted therapy for women facing this disease." Celldex informed that initial
sites are now open to screen patients in the US, and additional sites in the
US, Canada, and Australia, will open in early 2014. The Full Research Report
on Celldex Therapeutics, Inc. - including full detailed breakdown, analyst
ratings and price targets - is available to download free of charge at:

http://www.analystscorner.com/r/full_research_report/b443_CLDX

WellCare Health Plans, Inc. Research Report

On November 26, 2013, WellCare Health Plans, Inc. (WellCare) announced that
the Company was approved by the South Carolina Department of Health and Human
Services (SCDHHS) to offer Medicaid in Charleston, Chesterfield, Greenwood,
Kershaw, McCormick, and Spartanburg counties in the state, with effect from
January 1, 2014. WellCare reported that with the addition of these six
counties, it will provide Medicaid services to 45 out of 46 counties in South
Carolina. Further, WellCare announced that membership from Carolina Medical
Homes (CMH) is expected to transition to WellCare on January 1, 2014 as a
result of alterations SCDHHS is making to its Healthy Connections Choices
Medicaid managed care program and WellCare's pending purchase of certain
assets from CMH. Dave Shafer, President, WellCare of South Carolina,
commented, "This six county expansion will allow WellCare to provide Medicaid
services to beneficiaries in nearly every county in South Carolina. It will
also help us to ensure that almost all of the members transitioning from
Carolina Medical Homes will be able to continue their care with their current
primary care providers." The Full Research Report on WellCare Health Plans,
Inc. - including full detailed breakdown, analyst ratings and price targets -
is available to download free of charge at:

http://www.analystscorner.com/r/full_research_report/be48_WCG

EDITOR NOTES:

1.This is not company news. We are an independent source and our views do
    not reflect the companies mentioned.
2.Information in this release is fact checked and produced on a best efforts
    basis and reviewed by Nidhi Vatsal, a CFA charterholder. However, we are
    only human and are prone to making mistakes. If you notice any errors or
    omissions, please notify us below.
3.This information is submitted as a net-positive to companies mentioned, to
    increase awareness for mentioned companies to our subscriber base and the
    investing public.
4.If you wish to have your company covered in more detail by our team, or
    wish to learn more about our services, please contact us at
    pubco@EquityNewsNetwork.com.
5.For any urgent concerns or inquiries, please contact us at
    compliance@EquityNewsNetwork.com.
6.Are you a public company? Would you like to see similar coverage on your
    company? Send us a full investors' package to
    research@EquityNewsNetwork.com for consideration.

COMPLIANCE PROCEDURE

Content is researched, written and reviewed on a best-effort basis. This
document, article or report is prepared and authored by Equity News Network.
An outsourced research services provider represented by Nidhi Vatsal, CFA, has
only reviewed the information provided by Equity News Network in this article
or report according to the Procedures outlined by Equity News Network. Equity
News Network is not entitled to veto or interfere in the application of such
procedures by the outsourced provider to the articles, documents or reports,
as the case may be.

NOT FINANCIAL ADVICE

Equity News Network makes no warranty, expressed or implied, as to the
accuracy or completeness or fitness for a purpose (investment or otherwise),
of the information provided in this document. This information is not to be
construed as personal financial advice. Readers are encouraged to consult
their personal financial advisor before making any decisions to buy, sell or
hold any securities mentioned herein.

NO WARRANTY OR LIABILITY ASSUMED

Equity News Network is not responsible for any error which may be occasioned
at the time of printing of this document or any error, mistake or shortcoming.
No liability is accepted by Equity News Network whatsoever for any direct,
indirect or consequential loss arising from the use of this document. Equity
News Network expressly disclaims any fiduciary responsibility or liability for
any consequences, financial or otherwise arising from any reliance placed on
the information in this document. Equity News Network does not (1) guarantee
the accuracy, timeliness, completeness or correct sequencing of the
information, or (2) warrant any results from use of the information. The
included information is subject to change without notice.

CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA
Institute.

http://www.analystscorner.com/

SOURCE Analysts' Corner

Contact: CONTACT PERSON: Joe Thomas, CONTACT PHONE: +1-310-496-8071 (North
America)
 
Press spacebar to pause and continue. Press esc to stop.